נובוסבן אר.טי 1 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 2 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
נובוסבן אר.טי 5 מג בקבוקון
novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.
רפיקסיה 1000 יחבל
novo nordisk ltd., israel - nonacog beta pegol - אבקה וממס להכנת תמיסה להזרקה - nonacog beta pegol 1000 iu/vial - coagulation factor ix
קסינתה 500 יחבל
pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)
קסינתה 1000 יחבל
pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)
קסינתה 2000 יחבל
pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)
קסינתה 250 יחבל
pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 250 iu/vial - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)
נובואייט 1000 יחבל
novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1000 iu / 4 ml - coagulation factor viii
נובואייט 1500 יחבל
novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii